{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (M\u00e9dicament anti-ob\u00e9sit\u00e9 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'AOD-9604 ?<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) est un peptide synth\u00e9tique de 16 acides amin\u00e9s d\u00e9velopp\u00e9 par <strong>Metabolic Pharmaceuticals Ltd<\/strong> (Australie) \u00e0 la fin des ann\u00e9es 1990 comme analogue stabilis\u00e9 du fragment lipolytique C-terminal de l'hormone de croissance humaine. S\u00e9quence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, avec une extension tyrosine N-terminale qui stabilise le fragment parent hGH 177\u2013191, et un pont disulfure intramol\u00e9culaire Cys7\u2013Cys14). Formule mol\u00e9culaire C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>activit\u00e9 lipolytique et anti-lipog\u00e9nique<\/strong> de la mol\u00e9cule parente hGH mais ne <em>re\u00e7oit pas<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe de compos\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nom chimique<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604 (\u201cAnti-Obesity Drug 9604\u201d ; synonymes : Tyr-hGH 177-191 ; H-Tyr-(177-191 hGH fragment)-OH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3 (r\u00e9f\u00e9rence canonique Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815,1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Eu-Gly-Ser-Cys-Gly-Phe (lettre unique : YLRIVQCRSVEGSCGF ; 16 acides amin\u00e9s). Le pont disulfure intramol\u00e9culaire Cys7\u2013Cys14 forme une structure cyclique qui imite la g\u00e9om\u00e9trie disulfure de la r\u00e9gion parente hGH 182\u2013189. La tyrosine N-terminale est une addition synth\u00e9tique (non pr\u00e9sente dans l'hGH native 177\u2013191) qui stabilise le fragment contre la d\u00e9gradation prot\u00e9olytique amino-terminale.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>M\u00e9canisme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Lipolyse m\u00e9caniquement d\u00e9coupl\u00e9e<\/strong>. L'AOD-9604 ne se lie PAS au r\u00e9cepteur de l'hormone de croissance (GHR) \u2014 la surface de liaison au GHR de l'hGH native se situe dans la portion N-terminale (r\u00e9gion des r\u00e9sidus 1\u2013120), absente du fragment 176\u2013191. L'activit\u00e9 lipolytique \/ anti-lipog\u00e9nique est suppos\u00e9e \u00eatre m\u00e9di\u00e9e via la signalisation du r\u00e9cepteur \u03b23-adr\u00e9nergique et l'activation directe de la lipase sensible aux hormones (HSL) des adipocytes via cAMP-PKA. Le m\u00e9canisme reste incompl\u00e8tement caract\u00e9ris\u00e9 dans la litt\u00e9rature publi\u00e9e \u2014 il n'existe pas de r\u00e9cepteur unique confirm\u00e9 pour le fragment lipolytique C-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 minutes (tr\u00e8s court \u2014 d\u00fb \u00e0 la troncation prot\u00e9olytique N-terminale malgr\u00e9 la stabilisation par la Tyr). Cette courte demi-vie est l'une des principales hypoth\u00e8ses expliquant pourquoi l'essai de phase IIb sur l'ob\u00e9sit\u00e9 (2007) n'a pas atteint les crit\u00e8res de perte de poids \u2014 le fragment est d\u00e9grad\u00e9 avant qu'une exposition suffisante aux r\u00e9cepteurs ne puisse s'accumuler dans le tissu cible.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (v\u00e9rifi\u00e9 par HPLC) ; la spectrom\u00e9trie de masse MALDI-TOF confirme 1815,1 Da. Certificat d'analyse disponible sur demande.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Soluble dans l'eau bact\u00e9riostatique, l'eau st\u00e9rile, le PBS et l'acide ac\u00e9tique \u00e0 0,1 % \u00e0 \u22655 mg\/mL ; facilement soluble dans le DMSO \u00e0 \u226550 mg\/mL pour la pr\u00e9paration de stocks in vitro. Le pont disulfure Cys7\u2013Cys14 contraint la g\u00e9om\u00e9trie du peptide mais n'entrave pas la solubilit\u00e9 aqueuse.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C non ouvert pour le stock de travail \u00e0 court terme ; \u221220 \u00b0C pour le stockage \u00e0 long terme (stable \u226536 mois \u00e0 \u221220 \u00b0C ; \u226518 mois \u00e0 2\u20138 \u00b0C). Aqueux reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans les ~30 jours. Prot\u00e9ger de la lumi\u00e8re. \u00c9viter les cycles r\u00e9p\u00e9t\u00e9s de cong\u00e9lation-d\u00e9cong\u00e9lation de la solution reconstitu\u00e9e \u2014 le pont disulfure est stable \u00e0 un seul cycle de cong\u00e9lation-d\u00e9cong\u00e9lation, mais les cycles cumulatifs risquent de provoquer un brouillage des thiols libres et une agr\u00e9gation partielle.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'AOD-9604 ?<\/h2>\n<p><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d ; CAS 221231-10-3) est un peptide synth\u00e9tique de 16 acides amin\u00e9s d\u00e9velopp\u00e9 par <strong>Metabolic Pharmaceuticals Ltd<\/strong> \u00e0 l'Universit\u00e9 Monash \u00e0 Melbourne, en Australie, \u00e0 partir de la fin des ann\u00e9es 1990. Il s'agit d'un analogue stabilis\u00e9 du fragment lipolytique C-terminal de l'hormone de croissance humaine native (r\u00e9sidus 177\u2013191), auquel une tyrosine N-terminale a \u00e9t\u00e9 ajout\u00e9e pour ralentir la d\u00e9gradation prot\u00e9olytique amino-terminale. S\u00e9quence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), avec le pont disulfure intramol\u00e9culaire natif Cys182\u2013Cys189 de l'hGH parent conserv\u00e9 en tant que Cys7\u2013Cys14 dans la num\u00e9rotation du fragment. Masse mol\u00e9culaire 1815,1 g\/mol, formule empirique C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>effets promoteurs de croissance \/ anabolisants<\/strong> (m\u00e9di\u00e9s par le r\u00e9cepteur de l'hormone de croissance, la signalisation JAK2\/STAT5 et la production d'IGF-1 en aval) et <strong>effets lipolytiques \/ anti-lipog\u00e9niques<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/fr\/hgh-fragment-176-191\/\">Fragment HGH 176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Lipolyse d\u00e9coupl\u00e9e du GHR<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>Absence de liaison au r\u00e9cepteur de GH<\/strong> \u2014 La surface de liaison au GHR de l'hGH native est contenue dans la moiti\u00e9 N-terminale de la mol\u00e9cule (r\u00e9gion des r\u00e9sidus 1\u2013120), qui est absente du fragment AOD-9604 \/ 176\u2013191. En cons\u00e9quence, l'AOD-9604 ne se lie PAS au r\u00e9cepteur de l'hormone de croissance (GHR), n'active PAS la signalisation JAK2\/STAT5, n'induit PAS la production h\u00e9patique d'IGF-1, et ne produit PAS les effets promoteurs de croissance, stimulants des chondrocytes ou contre-r\u00e9gulateurs de l'insuline de la mol\u00e9cule <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> parente. C'est la propri\u00e9t\u00e9 pharmacologique <em>n\u00e9gative<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>Signalisation du r\u00e9cepteur \u03b23-adr\u00e9nergique (hypoth\u00e8se)<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>Activation de la lipase hormonosensible (HSL)<\/strong> \u2014 En aval de l'engagement du r\u00e9cepteur, l'AOD-9604 a \u00e9t\u00e9 rapport\u00e9 comme activant la lipase hormonosensible des adipocytes via une phosphorylation m\u00e9di\u00e9e par la PKA (la voie canonique d'activation de la lipolyse), entra\u00eenant l'hydrolyse des triglyc\u00e9rides en glyc\u00e9rol et acides gras libres. L'augmentation de la lib\u00e9ration d'acides gras libres dans la circulation a \u00e9t\u00e9 document\u00e9e dans des travaux in vivo publi\u00e9s sur des rongeurs apr\u00e8s administration d'AOD-9604.<\/li>\n<li><strong>Activit\u00e9 anti-lipog\u00e9nique<\/strong> \u2014 En plus de stimuler la lipolyse, l'AOD-9604 a \u00e9t\u00e9 rapport\u00e9 comme supprimant la lipogen\u00e8se de novo dans les adipocytes cultiv\u00e9s \u2014 r\u00e9duisant l'activit\u00e9 de l'ac\u00e9tyl-CoA carboxylase (ACC) et de la fatty-acid synthase (FAS) dans des tests de diff\u00e9renciation 3T3-L1. Le profil combin\u00e9 lipolyse-stimul\u00e9e\/lipogen\u00e8se-inhib\u00e9e est la pharmacologie canonique de \u201c mobilisation des graisses \u201d que le programme original Metabolic-Pharmaceuticals \u00e9tait con\u00e7u pour engager.<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>Le probl\u00e8me de la demi-vie de 4 minutes<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmacologie lipolytique d\u00e9coupl\u00e9e du GHR<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>Pharmacologie des r\u00e9cepteurs \u03b23-adr\u00e9nergiques (indirecte)<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>Pharmacologie comparative vs HGH 191AA et fragment HGH 176-191<\/strong> \u2014 des comparaisons publi\u00e9es c\u00f4te \u00e0 c\u00f4te de l'AOD-9604 avec l'HGH compl\u00e8te et le fragment 176-191 non stabilis\u00e9 ont caract\u00e9ris\u00e9 les profils diff\u00e9rentiels de liaison au GHR, d'induction d'IGF-1 et de lipolyse ; l'AOD-9604 se situe \u00e0 l'extr\u00e9mit\u00e9 \u201c lipolytique uniquement, sans axe de croissance \u201d de ce spectre<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/fr\/hgh-fragment-176-191\/\">Fragment HGH 176-191<\/a> (le fragment parent non stabilis\u00e9 \u2014 comparaison directe), <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> (la mol\u00e9cule parente compl\u00e8te \u2014 pour la pharmacologie comparative), <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> (Analogue de GHRH \u2014 stimulation en amont de l'axe HGH), <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> (Analogue de GHRH 1-29), et <a href=\"https:\/\/medsbase.com\/fr\/mots-c\/\">MOTS-c<\/a> (peptide m\u00e9tabolique d\u00e9riv\u00e9 des mitochondries). Parcourez l'int\u00e9gralit\u00e9 du <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">peptides &amp; compounds catalog<\/a>, ou consultez la s\u00e9lection de <a href=\"https:\/\/medsbase.com\/fr\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> hubs. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Culture cellulaire in-vitro et titration in-vivo de courte dur\u00e9e \u2014 tests de lipolyse des adipocytes 3T3-L1, pharmacologie des adipocytes primaires, panels dose-r\u00e9ponse, titration murine \u00e0 cohorte unique<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Comparaison \u2014 AOD-9604 vs fragment HGH 176-191<\/h2>\n<p>AOD-9604 et <a href=\"https:\/\/medsbase.com\/fr\/hgh-fragment-176-191\/\">Fragment HGH 176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragment HGH 176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>S\u00e9quence (lettre unique)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa ; avec stabilisation par Tyr N-terminale)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa) ou LRIVQCRSVEGSCGF (15 aa, non stabilis\u00e9) selon le lot du fournisseur ; consulter le COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815,1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817,06 g\/mol (qualit\u00e9 fournisseur 16-aa) ou 1654 g\/mol (15-aa non stabilis\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd (Universit\u00e9 Monash, Australie, fin des ann\u00e9es 1990)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~4 minutes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133 minutes (plus court, moins stable aux prot\u00e9ases)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fixation au r\u00e9cepteur de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun \u2014 n'interagit pas avec l'axe GHR\/JAK2\/STAT5\/IGF-1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun \u2014 m\u00eame propri\u00e9t\u00e9 ; les deux sont des fragments d\u00e9coupl\u00e9s du GHR<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Historique des essais cliniques<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">L'essai de phase IIb sur l'ob\u00e9sit\u00e9 (~500 patients, 2007) n'a pas atteint le crit\u00e8re principal ; programme abandonn\u00e9<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun programme de d\u00e9veloppement clinique formel<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">L\u00e9g\u00e8rement pr\u00e9f\u00e9r\u00e9 pour les travaux in vivo en raison de la demi-vie l\u00e9g\u00e8rement plus longue ; compos\u00e9 de r\u00e9f\u00e9rence pour les comparaisons structure-fonction<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Essais de lipolyse in vitro en culture cellulaire o\u00f9 la demi-vie courte est moins limitante<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/fr\/hgh-fragment-176-191\/\">Fragment HGH 176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Besoin d'eau BAC ?<\/strong> La reconstitution de tout flacon lyophilis\u00e9 n\u00e9cessite de l'eau bact\u00e9riostatique st\u00e9rile. Associez ce produit \u00e0 notre <a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 flacon multidose de 30 mL, pr\u00e9serv\u00e9 par 0,9 % d'alcool benzylique, qualit\u00e9 USP.<\/div>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stockage \u00e0 court terme. Pour un stockage \u00e0 long terme, congeler les flacons non ouverts \u00e0 \u221220 \u00b0C (stable \u226536 mois \u00e0 \u221220 \u00b0C ; \u226518 mois \u00e0 2\u20138 \u00b0C). Le pont disulfure Cys7\u2013Cys14 est stable \u00e0 l'\u00e9tat lyophilis\u00e9 et lors d'un stockage r\u00e9frig\u00e9r\u00e9 bref. Prot\u00e9ger de la lumi\u00e8re. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur le g\u00e2teau lyophilis\u00e9). Pour un flacon de 2 mg, 1,0 mL de diluant donne une solution de travail \u00e0 2 mg\/mL ; 0,5 mL donne 4 mg\/mL. Pour un flacon de 5 mg, 1,0 mL donne 5 mg\/mL ; 2,5 mL donne 2 mg\/mL. Pour un flacon de 10 mg, 1,0 mL donne 10 mg\/mL (limite pratique de solubilit\u00e9 en tampon aqueux) ; 5,0 mL donne 2 mg\/mL. L'AOD-9604 se dissout rapidement avec un l\u00e9ger mouvement circulaire \u00e0 temp\u00e9rature ambiante \u2014 g\u00e9n\u00e9ralement en 15 \u00e0 30 secondes. Une fois reconstitu\u00e9, conserver le flacon entre 2 et 8 \u00b0C et utiliser dans les 30 jours. Prot\u00e9ger de la lumi\u00e8re. <strong>\u00c9viter les cycles r\u00e9p\u00e9t\u00e9s de cong\u00e9lation-d\u00e9cong\u00e9lation du mat\u00e9riel reconstitu\u00e9<\/strong> \u2014 les cycles cumul\u00e9s de cong\u00e9lation-d\u00e9cong\u00e9lation risquent de provoquer un brouillage du pont disulfure Cys7\u2013Cys14 et une agr\u00e9gation partielle. Jeter en cas de turbidit\u00e9, de particules ou de changement marqu\u00e9 de couleur. <\/p>\n<h2>Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>Quelle est la diff\u00e9rence entre l'AOD-9604 et le fragment 176-191 de HGH ?<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/fr\/hgh-fragment-176-191\/\">Fragment HGH 176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>L'AOD-9604 est-il identique au HGH ?<\/h3>\n<p>Non. L'AOD-9604 est un fragment synth\u00e9tique de 16 acides amin\u00e9s du HGH couvrant uniquement la r\u00e9gion lipolytique C-terminale (r\u00e9sidus 176\u2013191 + Tyr en N-terminal). Le <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>Pourquoi l'essai de phase IIb sur l'ob\u00e9sit\u00e9 a-t-il \u00e9chou\u00e9 ?<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>Quel est le statut r\u00e9glementaire de l'AOD-9604 selon l'AMA ?<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>Quelle est la diff\u00e9rence entre l'AOD-9604 et les agonistes \u03b23-adr\u00e9nergiques directs comme le mirabegron ?<\/h3>\n<p>Le mirabegron et le CL-316,243 sont <em>activateur direct<\/em> des agonistes des r\u00e9cepteurs \u03b23-adr\u00e9nergiques \u2014 des petites mol\u00e9cules qui se lient au site orthost\u00e9rique du \u03b23-AR et activent la signalisation Gs-AMPc. L'AOD-9604 est un <em>activateur indirect<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>Oui \u2014 l'AOD-9604 cible une couche diff\u00e9rente de la biologie de l'axe HGH que la forme compl\u00e8te <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> ou les analogues de la GHRH (<a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/fr\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>Pourquoi l'AOD-9604 est-il parfois list\u00e9 \u00e0 1815,1 Da et parfois \u00e0 1817 Da ?<\/h3>\n<p>Cette divergence refl\u00e8te la diff\u00e9rence entre la masse monoisotopique (1815,1 Da, calcul\u00e9e \u00e0 partir de l'isotope le plus abondant de chaque atome) et la masse mol\u00e9culaire moyenne (1817,1 Da, calcul\u00e9e \u00e0 partir de la moyenne pond\u00e9r\u00e9e des masses isotopiques naturelles de chaque atome). Les deux sont correctes pour la m\u00eame mol\u00e9cule. La spectrom\u00e9trie de masse MALDI-TOF rapporte g\u00e9n\u00e9ralement la masse monoisotopique pour les peptides de cette taille ; la litt\u00e9rature plus ancienne et certains fournisseurs indiquent la masse moyenne. Pour les certificats d'analyse, le chiffre de 1815,1 Da est la valeur de r\u00e9f\u00e9rence canonique de Sigma-Aldrich. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/hgh-fragment-176-191\/\"><strong>Fragment HGH 176-191<\/strong><\/a> \u2014 Fragment parent non stabilis\u00e9 \u2014 homologue m\u00e9canistique direct, lipolyse d\u00e9coupl\u00e9e similaire du GHR<\/li>\n<li><a href=\"\/fr\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Mol\u00e9cule parente pleine longueur \u2014 pour la pharmacologie comparative avec engagement de l'axe GH<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analogue de la GHRH \u2014 stimulation en amont de l'axe HGH<\/li>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/fr\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 N\u00e9cessaire pour reconstituer tout flacon lyophilis\u00e9 \u2014 diluant st\u00e9rile, conserv\u00e9 avec 0,9% d'alcool benzylique<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragment lipolytique C-terminal 176-191 de hGH stabilis\u00e9 (extension N-terminale Tyr)<br \/>\n\u2705 D\u00e9velopp\u00e9 par Metabolic Pharmaceuticals Ltd (Universit\u00e9 Monash, fin des ann\u00e9es 1990)<br \/>\n\u2705 D\u00e9coupl\u00e9 du GHR \u2014 pas d'IGF-1, pas de JAK2\/STAT5, pas d'activation de l'axe de croissance<br \/>\n\u2705 Lipolytique + anti-lipog\u00e9nique ; d\u00e9pendant des \u03b23-AR (m\u00e9canisme incompl\u00e8tement caract\u00e9ris\u00e9)<br \/>\n\u2705 Demi-vie plasmatique d'environ 4 min ; essai de phase IIb contre l'ob\u00e9sit\u00e9 \u00e9chou\u00e9 (2007) ; MW 1815,1, CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}